H3B-6527

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameH3B-6527
Drug Alias NameH3B-6527
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 4 antagonists
TargetsFibroblast growth factor receptor 4
Therapy Area/IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesH3 Biomedicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesEisai IncH3 Biomedicine Inc
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A